These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26571798)

  • 21. Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C.
    Lin RJ; Moskovits T; Diefenbach CS; Hymes KB
    Blood Cancer J; 2016 Mar; 6(3):e402. PubMed ID: 26967819
    [No Abstract]   [Full Text] [Related]  

  • 22. Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient.
    Helmers RA; Byrne TJ; Wesselius LJ; Leslie KO
    Mayo Clin Proc; 2015 Sep; 90(9):1294-7. PubMed ID: 26231293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
    [No Abstract]   [Full Text] [Related]  

  • 24. What does it mean to put new hepatitis C drugs on a list of essential medicines?
    Urrutia J; Porteny T; Daniels N
    BMJ; 2016 Apr; 353():i2035. PubMed ID: 27106956
    [No Abstract]   [Full Text] [Related]  

  • 25. Gilead's interferon-free HCV combo approved.
    Nat Biotechnol; 2014 Nov; 32(11):1070. PubMed ID: 25380423
    [No Abstract]   [Full Text] [Related]  

  • 26. MSF pushes down price of generic hepatitis C drugs to new low level.
    Wise J
    BMJ; 2017 Nov; 359():j5054. PubMed ID: 29092825
    [No Abstract]   [Full Text] [Related]  

  • 27. [Simeprevir (Olysio), oral administration].
    Van Broeck D
    J Pharm Belg; 2015 Mar; (1):57-60. PubMed ID: 26571797
    [No Abstract]   [Full Text] [Related]  

  • 28. Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era.
    Berden FA; Kievit W; Baak LC; Bakker CM; Beuers U; Boucher CA; Brouwer JT; Burger DM; van Erpecum KJ; van Hoek B; Hoepelman AI; Honkoop P; Kerbert-Dreteler MJ; de Knegt RJ; Koek GH; van Nieuwkerk CM; van Soest H; Tan AC; Vrolijk JM; Drenth JP
    Neth J Med; 2014 Oct; 72(8):388-400. PubMed ID: 25387551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.
    Pellicelli AM; Montalbano M; Lionetti R; Durand C; Ferenci P; D'Offizi G; Knop V; Telese A; Lenci I; Andreoli A; Zeuzem S; Angelico M
    Dig Liver Dis; 2014 Oct; 46(10):923-7. PubMed ID: 24997638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
    D'Ambrosio R; Aghemo A; Colombo M
    Expert Opin Drug Saf; 2015 Mar; 14(3):473-84. PubMed ID: 25645644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
    Omata M; Nishiguchi S; Ueno Y; Mochizuki H; Izumi N; Ikeda F; Toyoda H; Yokosuka O; Nirei K; Genda T; Umemura T; Takehara T; Sakamoto N; Nishigaki Y; Nakane K; Toda N; Ide T; Yanase M; Hino K; Gao B; Garrison KL; Dvory-Sobol H; Ishizaki A; Omote M; Brainard D; Knox S; Symonds WT; McHutchison JG; Yatsuhashi H; Mizokami M
    J Viral Hepat; 2014 Nov; 21(11):762-8. PubMed ID: 25196837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expensiveness of hepatitis C virus polymerase inhibitor sofosbuvir: a warrant for therapeutic drug monitoring of compliance.
    Colson P; Gérolami R
    Clin Microbiol Infect; 2015 Apr; 21(4):e32. PubMed ID: 25658571
    [No Abstract]   [Full Text] [Related]  

  • 33. Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
    Sofia MJ
    Antiviral Res; 2014 Jul; 107():119-24. PubMed ID: 24792751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C.
    Kumar S; Jacobson IM
    J Hepatol; 2014 Nov; 61(1 Suppl):S91-7. PubMed ID: 25443349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation.
    Kim B; Trivedi A; Thung SN; Grewal P
    Semin Liver Dis; 2014 Feb; 34(1):108-12. PubMed ID: 24782264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection.
    Ollendorf DA; Tice JA; Pearson SD
    JAMA Intern Med; 2014 Jul; 174(7):1170-1. PubMed ID: 24798321
    [No Abstract]   [Full Text] [Related]  

  • 38. Sovaldi ushers in wave of costly hepatitis C drugs.
    Manag Care; 2014 Jan; 23(1):51. PubMed ID: 24765752
    [No Abstract]   [Full Text] [Related]  

  • 39. Direct-acting antiviral agents for the treatment of HCV.
    Thompson AJ; Locarnini S
    Antivir Ther; 2012; 17(6 Pt B):1105-7. PubMed ID: 23188736
    [No Abstract]   [Full Text] [Related]  

  • 40. A Patient of Chronic Hepatitis C Complicated by Thalassemia Major and Chronic Osteomyelitis: A Therapeutic Challenge for a Clinician.
    Sarkar R; Paul R; Roy D; Ghosh R; Sau TJ; Lahiri G; Ruia AV
    J Assoc Physicians India; 2018 Mar; 66(3):96-7. PubMed ID: 30341885
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.